Published in Biomed Imaging Interv J on January 01, 2007
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys (2000) 4.99
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med (2005) 3.26
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol (2000) 2.77
Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys (1996) 2.70
18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys (1999) 2.27
CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology (1991) 1.94
Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology (1999) 1.88
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol (2006) 1.73
Assessment of 18F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiother Oncol (2006) 1.67
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging (2006) 1.67
Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol (2001) 1.64
Dose-volume histograms. Int J Radiat Oncol Biol Phys (1991) 1.62
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med (2002) 1.62
Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.52
Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation. Radiother Oncol (2005) 1.39
The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.30
The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol (2000) 1.26
Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun (2006) 1.23
Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. Int J Radiat Oncol Biol Phys (2003) 1.11
Imaging in cervical cancer. Cancer (2003) 1.08
Intensity-modulated radiotherapy. Cancer J (2002) 1.07
Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer (1999) 1.06
Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging (2005) 1.05
Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.03
A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy. Radiother Oncol (2006) 1.01
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging (2006) 1.00
Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg (2001) 0.99
A local contrast based approach to threshold segmentation for PET target volume delineation. Med Phys (2006) 0.96
Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys (2002) 0.96
Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging (2005) 0.93
State-of-the-Art FDG-PET imaging of lung cancer. Semin Roentgenol (2005) 0.93
Thresholding in PET images of static and moving targets. Phys Med Biol (2005) 0.92
Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med (2006) 0.91
Lung cancer staging classification. Clin Chest Med (1993) 0.89
Lymph node imaging: basic principles. Eur J Radiol (2006) 0.89
Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol (2004) 0.88
Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am (2004) 0.86
PET scanning in lung cancer: current status and future directions. Semin Surg Oncol (2003) 0.84
The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer. Can J Urol (2006) 0.82
Assessment of therapy response by FDG PET in pediatric patients. Q J Nucl Med (2003) 0.81
Display of positron emission tomography with Cadplan. Australas Phys Eng Sci Med (2002) 0.80
Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET. Eur J Nucl Med Mol Imaging (2002) 0.80
Monte Carlo-based lung cancer treatment planning incorporating PET-defined target volumes. J Appl Clin Med Phys (2005) 0.78
Developments in radiotherapy. Acta Oncol (2003) 0.78
Fluorodeoxyglucose positron emission tomography for melanoma staging: refining the indications. Ann Surg Oncol (2006) 0.77
Role of PET scan in management of oesophageal cancer. Eur J Surg Oncol (2005) 0.76
Rgt1p of Saccharomyces cerevisiae, a key regulator of glucose-induced genes, is both an activator and a repressor of transcription. Mol Cell Biol (1996) 1.85
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood (1996) 1.54
Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore) (1996) 1.46
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
A demonstration of the intrinsic importance of stabilizing hydrophobic binding and non-covalent van der Waals contacts dominant in the non-covalent CC-1065/B-DNA binding. Chem Biol Interact (1990) 1.24
A new approach to the synthesis of a protected 2-aminopurine derivative and its incorporation into oligodeoxynucleotides containing the Eco RI and Bam HI recognition sites. Nucleic Acids Res (1988) 1.17
Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys (2001) 1.05
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma (1999) 1.02
Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br J Ophthalmol (1991) 1.00
Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer (1997) 0.96
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol (2001) 0.94
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer (2004) 0.93
Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol (2012) 0.91
The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry. Lung (2014) 0.91
Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med (2011) 0.91
Increasing the use of an existing medical emergency team in a teaching hospital. Anaesth Intensive Care (2006) 0.90
The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer (2009) 0.88
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer (2005) 0.88
Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer (2010) 0.87
Seizures in children with supratentorial astroglial neoplasms. Pediatr Neurosurg (1994) 0.87
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs (2006) 0.86
FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer (2011) 0.86
Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood (1994) 0.84
Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass. Br J Anaesth (2013) 0.84
Influence of F-fluorodeoxyglucose-positron emission tomography on computed tomography-based radiation treatment planning for oesophageal cancer. Australas Radiol (2006) 0.83
Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol (1998) 0.83
Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys (1997) 0.83
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol (2000) 0.83
Chemoradiotherapy in the management of primary squamous-cell carcinoma of the rectum. Colorectal Dis (2011) 0.83
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma (1999) 0.83
Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clin Exp Dermatol (2011) 0.83
Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group. Blood (1995) 0.82
Life-span, T-cell responses, and incidence of lymphomas in congenic mice. Proc Natl Acad Sci U S A (1995) 0.80
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. Br J Cancer (2008) 0.79
Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature. Ann Oncol (2001) 0.78
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol (1998) 0.78
Geographic miss in radiation oncology: have we missed the boat? J Med Imaging Radiat Oncol (2009) 0.78
Shunt nephritis. Case report. J Neurosurg (1991) 0.78
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol (2001) 0.78
A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia (1995) 0.76
Management of seminoma of the testis: recommendations based on treatment results. Aust N Z J Surg (1997) 0.75
What can paper-based clinical information systems tell us about the design of computerized clinical information systems (CIS) in the ICU? Aust Crit Care (2010) 0.75
A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma. Invest New Drugs (1995) 0.75
AT heterozygosity in a patient with multiple myeloma. Clin Oncol (R Coll Radiol) (2003) 0.75
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leuk Lymphoma (1995) 0.75
Chest pain in an 18-year-old man: "didn't I tell you I was sick?". Ir Med J (2009) 0.75
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). Am J Clin Oncol (2001) 0.75
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Semin Oncol (1997) 0.75
Treatment of adult patients with acute lymphocytic leukemia in relapse. Leuk Lymphoma (1996) 0.75